Share This Article:

Prevalence and Characteristics of Treatment-Resistant Hypertension among Hypertensive Japanese Outpatients

Abstract Full-Text HTML XML Download Download as PDF (Size:363KB) PP. 623-634
DOI: 10.4236/ijcm.2015.69083    3,025 Downloads   3,444 Views   Citations

ABSTRACT

Aims: To retrospectively investigate the prevalence and characteristics of treatment-resistant hypertension (R-HT) among consecutive hypertensive outpatients, since patients with R-HT are candidates for catheter-based renal sympathetic denervation (RD). Methods: Consecutive hypertensive outpatients (n = 999) were recruited in our hospital. R-HT patients who were candidates for RD had clinic systolic blood pressure > 160 mmHg despite taking three or more antihypertensive drugs including at least one diuretics at higher than standard doses. Results: Our survey indicated that only 26 patients (2.6%) were potential candidates for renal denervation. Candidates for RD showed a significantly higher age (P < 0.005), brain natriuretic peptide level (P = 0.0001), urinary albumin/creatinine excretion ratio in spot urine (P < 0.005), pulse wave velocity (P < 0.01), left ventricular end-diastolic diameter (P < 0.005), and interventricular septal thickness (P < 0.005) than the other 973 patients. Candidates for denervation had a significantly lower hemoglobin (P = 0.0001), serum albumin (P < 0.001), eGFR (P < 0.0005), plasma renin activity (P = 0.0001), and plasma aldosterone level (P < 0.005) than other patients, while their urinary sodium/creatinine ratio was higher, indicating that patients with R-HT appeared to have a high salt intake. Conclusion: Our retrospective clinical survey indicated that only 0.5% of Japanese hypertensive outpatients (5/999 patients) were candidates for RD. Therefore, establishment of hypertension cohort network will be essential to recruit R-HT patients for RD.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Okamura, K. and Urata, H. (2015) Prevalence and Characteristics of Treatment-Resistant Hypertension among Hypertensive Japanese Outpatients. International Journal of Clinical Medicine, 6, 623-634. doi: 10.4236/ijcm.2015.69083.

References

[1] Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T., Mehlsen, J., Nieminen, M., O’Brien, E. and Ostergren, J. (2005) Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. The Lancet, 366, 895-906.
http://dx.doi.org/10.1016/S0140-6736(05)67185-1
[2] Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparil, S. and Wedel, H. (2002) Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol. The Lancet, 359, 995-1003.
http://dx.doi.org/10.1016/S0140-6736(02)08089-3
[3] Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P. and Anderson, C. (2008) Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. The New England Journal of Medicine, 358, 1547-1559.
http://dx.doi.org/10.1056/NEJMoa0801317
[4] Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H. and Hishida, A. (2009) Revised Equations for Estimated GFR from Serum Creatinine in Japan. American Journal of Kidney Diseases, 53, 982-992.
http://dx.doi.org/10.1053/j.ajkd.2008.12.034
[5] Persell, S.D. (2011) Prevalence of Resistant Hypertension in the United States, 2003-2008. Hypertension, 57, 1076-1080.
http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.170308
[6] The INTERSALT Co-Operative Research Group (1989) Appendix Tables. Centre-Specific Results by Age and Sex. Journal of Human Hypertension, 3, 331-407.
[7] Funder, J.W., Carey, R.M., Fardella, C., Gomez-Sanchez, C.E., Mantero, F., Stowasser, M., Young Jr., W.F. and Montori, V.M. (2008) Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 93, 3266-3281.
http://dx.doi.org/10.1210/jc.2008-0104
[8] Kawano, Y., Tsuchihashi, T., Matsuura, H., Ando, K., Fujita, T. and Ueshima, H. (2007) Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of Salt Intake in the Management of Hypertension. Hypertension Research, 30, 887-893.
http://dx.doi.org/10.1291/hypres.30.887
[9] Schlaich, M.P., Schmieder, R.E., Bakris, G., Blankestijn, P.J., Bohm, M., Campese, V.M., Francis, D.P., Grassi, G., Hering, D., Katholi, R., Kjeldsen, S., Krum, H., Mahfoud, F., Mancia, G., Messerli, F.H., Narkiewicz, K., Parati, G., Rocha-Singh, K.J., Ruilope, L.M., Rump, L.C., Sica, D.A., Sobotka, P.A., Tsioufis, C., Vonend, O., Weber, M.A., Williams, B., Zeller, T. and Esler, M.D. (2013) International Expert Consensus Statement: Percutaneous Transluminal Renal Denervation for the Treatment of Resistant Hypertension. Journal of the American College of Cardiology, 62, 2031-2045.
http://dx.doi.org/10.1016/j.jacc.2013.08.1616
[10] Esler, M.D., Krum, H., Sobotka, P.A., Schlaich, M.P., Schmieder, R.E. and Bohm, M. (2010) Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial. The Lancet, 376, 1903-1909.
http://dx.doi.org/10.1016/S0140-6736(10)62039-9
[11] Kandzari, D.E., Bhatt, D.L., Sobotka, P.A., O’Neill, W.W., Esler, M., Flack, J.M., Katzen, B.T., Leon, M.B., Massaro, J.M., Negoita, M., Oparil, S., Rocha-Singh, K., Straley, C., Townsend, R.R. and Bakris, G. (2012) Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial. Clinical Cardiology, 35, 528-535.
http://dx.doi.org/10.1002/clc.22008
[12] Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., White, A., Cushman, W.C., White, W., Sica, D., Ferdinand, K., Giles, T.D., Falkner, B. and Carey, R.M. (2008) Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 51, 1403-1419.
http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.189141
[13] Nishizaka, M.K., Pratt-Ubunama, M., Zaman, M.A., Cofield, S. and Calhoun, D.A. (2005) Validity of Plasma Aldosterone-to-Renin Activity Ratio in African American and White Subjects with Resistant Hypertension. American Journal of Hypertension, 18, 805-812.
http://dx.doi.org/10.1016/j.amjhyper.2005.01.002
[14] Tanaka, T., Okamura, T., Miura, K., Kadowaki, T., Ueshima, H., Nakagawa, H. and Hashimoto, T. (2002) A Simple Method to Estimate Populational 24-h Urinary Sodium and Potassium Excretion Using a Casual Urine Specimen. Journal of Human Hypertension, 16, 97-103.
http://dx.doi.org/10.1038/sj.jhh.1001307
[15] Hayek, S.S., Abdou, M.H., Demoss, B.D., Legaspi, J.M., Veledar, E., Deka, A., Krishnan, S.K., Wilmot, K.A., Patel, A.D., Kumar, V.R. and Devireddy, C.M. (2013) Prevalence of Resistant Hypertension and Eligibility for Catheter-Based Renal Denervation in Hypertensive Outpatients. American Journal of Hypertension, 26, 1452-1458.
http://dx.doi.org/10.1093/ajh/hpt132
[16] Miura, K., Nagai, M. and Ohkubo, T. (2013) Epidemiology of Hypertension in Japan: Where Are We Now? Circulation Journal, 77, 2226-2231.
http://dx.doi.org/10.1253/circj.CJ-13-0847
[17] Prochnau, D., Heymel, S., Gobel, B., Figulla, H.R. and Surber, R. (2013) Resistant Hypertension: Multivariate Predictors of Blood Pressure Response to Renal Denervation. International Journal of Cardiology, 168, 3130-3132.
http://dx.doi.org/10.1016/j.ijcard.2013.04.035
[18] Zhou, H.H., Koshakji, R.P., Silberstein, D.J., Wilkinson, G.R. and Wood, A.J. (1989) Altered Sensitivity to and Clearance of Propranolol in Men of Chinese Descent as Compared with American Whites. New England Journal of Medicine, 320, 565-570.
http://dx.doi.org/10.1056/NEJM198903023200905
[19] Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., White, A., Cushman, W.C., White, W., Sica, D., Ferdinand, K., Giles, T.D., Falkner, B. and Carey, R.M. (2008) Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 117, e510-e526.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.189141
[20] Bramley, T.J., Gerbino, P.P., Nightengale, B.S. and Frech-Tamas, F. (2006) Relationship of Blood Pressure Control to Adherence with Antihypertensive Monotherapy in 13 Managed Care Organizations. Journal of Managed Care Pharmacy, 12, 239-245.
[21] Corrao, G., Parodi, A., Nicotra, F., Zambon, A., Merlino, L., Cesana, G. and Mancia, G. (2011) Better Compliance to Antihypertensive Medications Reduces Cardiovascular Risk. Journal of Hypertension, 29, 610-618.
http://dx.doi.org/10.1097/HJH.0b013e328342ca97
[22] Claxton, A.J., Cramer, J. and Pierce, C. (2001) A Systematic Review of the Associations between Dose Regimens and Medication Compliance. Clinical Therapeutics, 23, 1296-1310.
http://dx.doi.org/10.1016/S0149-2918(01)80109-0
[23] Thom, S., Poulter, N., Field, J., Patel, A., Prabhakaran, D., Stanton, A., Grobbee, D.E., Bots, M.L., Reddy, K.S., Cidambi, R., Bompoint, S., Billot, L. and Rodgers, A. (2013) Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients with or at High Risk of CVD: The UMPIRE Randomized Clinical Trial. JAMA, 310, 918-929.
http://dx.doi.org/10.1001/jama.2013.277064
[24] Dorenkamp, M., Bonaventura, K., Leber, A.W., Boldt, J., Sohns, C., Boldt, L.H., Haverkamp, W., Frei, U. and Roser, M. (2013) Potential Lifetime Cost-Effectiveness of Catheter-Based Renal Sympathetic Denervation in Patients with Resistant Hypertension. European Heart Journal, 34, 451-461.
http://dx.doi.org/10.1093/eurheartj/ehs355
[25] Geisler, B.P., Egan, B.M., Cohen, J.T., Garner, A.M., Akehurst, R.L., Esler, M.D. and Pietzsch, J.B. (2012) Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology, 60, 1271-1277.
http://dx.doi.org/10.1016/j.jacc.2012.07.029
[26] Pokushalov, E., Romanov, A., Corbucci, G., Artyomenko, S., Baranova, V., Turov, A., Shirokova, N., Karaskov, A., Mittal, S. and Steinberg, J.S. (2012) A Randomized Comparison of Pulmonary Vein Isolation with versus without Concomitant Renal Artery Denervation in Patients with Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension. Journal of the American College of Cardiology, 60, 1163-1170.
http://dx.doi.org/10.1016/j.jacc.2012.05.036
[27] Mahfoud, F., Cremers, B., Janker, J., Link, B., Vonend, O., Ukena, C., Linz, D., Schmieder, R., Rump, L.C., Kindermann, I., Sobotka, P.A., Krum, H., Scheller, B., Schlaich, M., Laufs, U. and Bohm, M. (2012) Renal Hemodynamics and Renal Function after Catheter-Based Renal Sympathetic Denervation in Patients with Resistant Hypertension. Hypertension, 60, 419-424.
http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.193870
[28] Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M.C., Hoppe, U.C., Vonend, O., Rump, L.C., Sobotka, P.A., Krum, H., Esler, M. and Bohm, M. (2011) Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients with Resistant Hypertension: A Pilot Study. Circulation, 123, 1940-1946.
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.991869
[29] Witkowski, A., Prejbisz, A., Florczak, E., Kadziela, J., Sliwinski, P., Bielen, P., Michalowska, I., Kabat, M., Warchol, E., Januszewicz, M., Narkiewicz, K., Somers, V.K., Sobotka, P.A. and Januszewicz, A. (2011) Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients with Resistant Hypertension and Sleep Apnea. Hypertension, 58, 559-565.
http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173799
[30] Hering, D., Lambert, E.A., Marusic, P., Ika-Sari, C., Walton, A.S., Krum, H., Sobotka, P.A., Mahfoud, F., Bohm, M., Lambert, G.W., Esler, M.D. and Schlaich, M.P. (2013) Renal Nerve Ablation Reduces Augmentation Index in Patients with Resistant Hypertension. Journal of Hypertension, 31, 1893-1900.
http://dx.doi.org/10.1097/HJH.0b013e3283622e58
[31] Brandt, M.C., Mahfoud, F., Reda, S., Schirmer, S.H., Erdmann, E., Bohm, M. and Hoppe, U.C. (2012) Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients with Resistant Hypertension. Journal of the American College of Cardiology, 59, 901-909.
http://dx.doi.org/10.1016/j.jacc.2011.11.034
[32] Lenski, D., Kindermann, I., Lenski, M., Ukena, C., Bunz, M., Mahfoud, F. and Bohm, M. (2013) Anxiety, Depression, Quality of Life and Stress in Patients with Resistant Hypertension before and after Catheter-Based Renal Sympathetic Denervation. EuroIntervention, 9, 700-708.
[33] Lambert, G.W., Hering, D., Esler, M.D., Marusic, P., Lambert, E.A., Tanamas, S.K., Shaw, J., Krum, H., Dixon, J.B., Barton, D.A. and Schlaich, M.P. (2012) Health-Related Quality of Life after Renal Denervation in Patients with Treatment-Resistant Hypertension. Hypertension, 60, 1479-1484.
http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.200865

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.